HSPPC-96
Sponsors
Agenus Inc., University of California, San Francisco, Alliance for Clinical Trials in Oncology, Rabih Said, National Cancer Institute (NCI)
Conditions
Brain and Central Nervous System TumorsGlioblastomaGliosarcomaKidney CancerLung CancerMelanomaNon-Small-Cell Lung CarcinomaPulmonary Cancer
Phase 1
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
CompletedNCT00293423
Start: 2005-11-18End: 2013-01-12Updated: 2021-05-13
Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma
WithdrawnNCT02452281
Start: 2015-12-31End: 2018-12-31Updated: 2016-01-25
Phase 2
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
CompletedNCT00098085
Start: 2003-09-30Target: 20Updated: 2009-03-09
HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM
CompletedNCT00905060
Start: 2009-06-29End: 2014-06-03Updated: 2021-03-24
Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence
TerminatedNCT01147536
Start: 2010-01-31End: 2012-06-30Updated: 2021-06-03
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
TerminatedNCT01814813
Start: 2013-06-19End: 2023-05-22Updated: 2025-01-24
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
TerminatedNCT03018288
Start: 2017-09-21End: 2022-12-20Updated: 2025-08-08